
CLAIMS

What is claimed is:


1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof,



Formula (I),

wherein:

A_1 is



;


R_1 is halogen, hydrogen, or cyano;

R_{3a} and R_5 are each independently hydrogen, halogen, or lower alkyl;

R_{52} is lower alkyl, lower cycloalkyl or lower haloalkyl;

R_{3b} is halogen;

W is a diazole optionally substituted with lower alkyl, lower cycloalkyl, or lower haloalkyl;

B_1 is  ,

R_{20} is halogen, hydrogen, lower alkyl, or lower haloalkyl; and

R_{26} is hydrogen, or halogen;

provided the compound is not (2-fluoro-5-hydroxyphenyl)(6-(3-methyl-1-(o-tolyl)-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl)methanone.

2. The compound of claim 1, wherein

R_1 is hydrogen, fluoro, or cyano;

R_{3a} and R_5 are each independently hydrogen, halogen, or methyl;

R_{52} is lower alkyl, cyclopropyl or lower haloalkyl;


R_{3b} is fluoro;

W is a diazole optionally substituted with one of methyl, cyclopropyl, or CF_3;

R_{20} is fluoro or chloro, methyl, or CF_3; and

R_{26} is hydrogen, fluoro or chloro.

3. The compound of claim 2, wherein W is selected from the group consisting of:


 , and ,


wherein * indicates a covalent bond to B_1; and


R_{30}, R_{31}, R_{32} and R_{33} are each independently hydrogen, lower alkyl, lower haloalkyl, or lower cycloalkyl, provided that at least one of R_{31} and R_{33} and at least one of R_{32} and R_{33} is not hydrogen.

4. The compound of claim 3, wherein R_{30}, R_{31}, R_{32} and R_{33} are each independently hydrogen, methyl, CF_3, or cyclopropyl, provided that at least one of R_{31} and R_{33} and at least one of R_{32} and R_{33} is not hydrogen.

5. The compound of claim 4, wherein W is selected from the group consisting of:




,



, and


,


wherein * indicates a covalent bond to B_1.

6. The compound of claim 5, wherein W is



, wherein * indicates a covalent bond to B_1, and R_{30} is methyl.

7. The compound of claim 5, wherein W is


, wherein * indicates a covalent bond to B_1, and R_{31} and R_{33} are each independently hydrogen, methyl, CF_3, or cyclopropyl, provided that one of R_{31} and R_{33} is hydrogen.

8. The compound of claim 5, wherein W is  , wherein * indicates a covalent bond to B_1, and R_{32} and R_{33} are each independently hydrogen, methyl, CF_3, or cyclopropyl, provided that one of R_{32} and R_{33} is hydrogen.

9. The compound of any one of claims 4-8, wherein A_1 is


.

10. The compound of claim 9, wherein R_5 is hydrogen.


11. The compound of claim 10, wherein R_1 is fluoro.

12. The compound of claim 11, wherein R_{3a} is hydrogen, fluoro, or methyl.

13. The compound of claim 12, wherein R_{3a} is hydrogen.

14. The compound of claim 13, wherein R_{20} is methyl, and R_{26} is hydrogen or fluoro; or R_{20} is chloro, fluoro or CF_3, and R_{26} is hydrogen.

15. The compound of any one of claims 4-8, wherein A_1 is


.

16. The compound of claim 15, wherein R_{52} is lower alkyl optionally substituted with one or more fluoro and cyclopropyl.


17. The compound of claim 16, wherein R_{3b} is fluoro.

18. The compound of claim 17, wherein

R_{20} is methyl, and R_{26} is hydrogen or fluoro; or

R_{20} is fluoro or CF_3, and R_{26} is hydrogen.

19. A compound of Formula (II-B) or a pharmaceutically acceptable salt thereof:



Formula (II-B),

wherein

R_1 is halogen or cyano;

R_3 is hydrogen, lower alkyl, or halogen;

R_5 is hydrogen, halogen or lower alkyl;

R_{20} is halogen or lower alkyl optionally substituted with one or more halogen;

R_{26} is halogen or hydrogen; and

R_{30} is hydrogen or lower alkyl optionally substituted with one or more halogen, provided the compound is not (2-fluoro-5-hydroxyphenyl)(6-(3-methyl-1-(o-tolyl)-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl)methanone.

20. The compound of claim 19, wherein

R_1 is F or cyano;

R_3 is hydrogen, methyl, or F;


R_5 is hydrogen, F or methyl;

R_{20} is F, methyl, or CF_3;

R_{26} is hydrogen or F; and

R_{30} is hydrogen, methyl or CF_3, provided the compound is not (2-fluoro-5-hydroxyphenyl)(6-(3-methyl-1-(o-tolyl)-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl)methanone.

21. A compound of Formula (II-C) or a pharmaceutically acceptable salt thereof:



Formula (II-C),

wherein

R_1 is halogen or cyano;

R_3 is hydrogen, lower alkyl, or halogen;

R_5 is hydrogen, halogen or lower alkyl;

R_{20} is halogen or lower alkyl optionally substituted with one or more halogen;

R_{26} is hydrogen or halogen; and

R_{31} and R_{33} are each independently hydrogen or lower alkyl optionally substituted with one or more halogen, provided that one of R_{31} and R_{33} is hydrogen.

22. The compound of claim 21, wherein

R_1 is F or cyano;

R_3 is hydrogen, methyl, or F;


R_5 is hydrogen, F or methyl;

R_{20} is F, methyl, or CF_3;

R_{26} is hydrogen or F; and

R_{31} and R_{33} are each independently hydrogen, methyl or CF_3.

23. A compound of Formula (II-D) or a pharmaceutically acceptable salt thereof:



wherein

R_1 is halogen or cyano;

R_3 is hydrogen, lower alkyl, or halogen;

R_5 is hydrogen, halogen or lower alkyl;

R_6 is hydrogen;

R_{20} is halogen or lower alkyl optionally substituted with one or more halogen;

R_{26} is halogen or hydrogen; and

R_{32} and R_{33} are each independently hydrogen or lower alkyl optionally substituted with one or more halogen, provided that one of R_{32} and R_{33} is hydrogen.

24. The compound of claim 23, wherein

R_1 is F or cyano;

R_3 is hydrogen, F or methyl;


R_5 is hydrogen, F or methyl;

R_{20} is F or methyl, or CF_3;

R_{26} is hydrogen or F; and

R_{32} and R_{33} are each independently hydrogen, methyl or, CF_3 provided that one of R_{32} and R_{33} is hydrogen.

25. A compound of Formula (III-B) or a pharmaceutically acceptable salt thereof:



Formula (III-B)

wherein

R_3 is halogen;

R_{52} is lower alkyl or lower cycloalkyl, each optionally substituted with halogen,

R_{30} is lower alkyl;

R_{20} is lower alkyl; and

R_{26} is hydrogen or halogen.

26. The compound of claim 25, wherein

R_3 is F;


R_{52} is lower alkyl optionally substituted with one or more F or cyclopropyl;

R_{30} is methyl;

R_{20} is methyl; and

R_{26} is hydrogen or F.

27. A compound of Formula (III-C) or a pharmaceutically acceptable salt thereof:



wherein

R_3 is halogen;

R_{52} is lower alkyl or lower cycloalkyl, each optionally substituted with halogen,

R_{31} and R_{33} are each independently hydrogen or lower alkyl optionally substituted with one or more halogen, provided that one of R_{31} and R_{33} is hydrogen.

R_{20} is lower alkyl optionally substituted with halogen; and

R_{26} is hydrogen or halogen.

28. The compound of claim 27, wherein

R_3 is F;


R_{52} is lower alkyl optionally substituted with one or more F; or cyclopropyl;

R_{31} and R_{33} are each independently hydrogen, methyl or CF_3, provided that one of R_{31} and R_{33} is hydrogen;

R_{20} is methyl or CF_3; and

R_{26} is hydrogen or F.

29. A compound of Formula (III-D) or a pharmaceutically acceptable salt thereof:



Formula (III-D)

wherein

R_3 is halogen;

R_{52} is lower alkyl or lower cycloalkyl, each optionally substituted with halogen,

R_{32} and R_{33} are each independently hydrogen or lower alkyl optionally substituted with one or more halogen, provided that one of R_{32} and R_{33} is hydrogen.

R_{20} is lower alkyl optionally substituted with halogen; and

R_{26} is hydrogen or halogen.

30. The compound of claim 29, wherein

R_3 is F;


R_{52} is lower alkyl optionally substituted with one or more F, or cyclopropyl;

R_{32} and R_{33} are each independently hydrogen, methyl or CF_3, provided that one of R_{32} and R_{33} is hydrogen;

R_{20} is methyl or CF_3; and

R_{26} is hydrogen or F.

31. A compound of Formula (II), or a pharmaceutically acceptable salt thereof,



Formula (II),

wherein

the dashed line represents an optional double bond;

R_1 is halogen;

R_3 is hydrogen;

W is A;


A is a 5-member heteroaryl ring optionally substituted with one or more R_{30};

R_{20} is halogen or lower alkyl optionally substituted with one or more halogen;

R_{30} is lower alkyl optionally substituted with one or more halogen; and


R_{26} is halogen or hydrogen, provided the compound is not (2-fluoro-5-hydroxyphenyl)(6-(3-methyl-1-(o-tolyl)-1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl)methanone.

32. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

33. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

34. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

35. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

36. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.


37. The compound of claim 1, wherein the compound is


, or a pharmaceutically acceptable salt thereof.


38. The compound of claim 1, wherein the compound is


, or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1, wherein the compound is


, or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1, wherein the compound is


, or a pharmaceutically acceptable salt thereof.